Hologic HOLX Stock: Hold or Sell as it Nears the End of Public Phase?

Hologic (HOLX) shares closed at $75.05, down 0.1%, after a special stockholder meeting approved a take-private proposal. The company's valuation looks stretched, with a forward 12-month price/sales ratio of 3.84X, above its median and the sector average. Hologic's Diagnostics division reported disappointing Q1 results, with revenues down 2.7% in constant currency. The company's Breast Health business received FDA approval for its Aptima HPV Assay.